WeVote
Log In

Bill

Bill

SB 1907

AFFORDABLE DRUG MANUFACTURING

104th Regular Session Introduced by Mike Simmons-Gessesse

SB 1907 - AFFORDABLE DRUG MANUFACTURING OverviewBill Number: SB 1907 Title: AFFORDABLE DRUG MANUFACTURING Status: Referred to Assignments Introduced: March 05, 2025 Purpose and

0
WeVote Research Nonpartisan
Bill Summary · SB 1907

SB 1907 - AFFORDABLE DRUG MANUFACTURING

Overview

Bill Number: SB 1907
Title: AFFORDABLE DRUG MANUFACTURING
Status: Referred to Assignments
Introduced: March 05, 2025

Purpose and Intent

The primary goal of SB 1907 is to establish a state-run pharmaceutical manufacturing program to produce affordable generic drugs and insulin. The bill aims to address the high cost of prescription medications, which has become a significant burden for many individuals and families. By creating a state-run manufacturing capability, the legislation seeks to increase access to essential drugs and drive down prices through competition with private pharmaceutical companies.

Key Provisions

  • Establishes the Affordable Drug Manufacturing Program within the state's Department of Health
  • Directs the program to manufacture and distribute generic drugs and insulin at the lowest possible price
  • Requires the program to prioritize the production of drugs that are in short supply or have experienced significant price increases
  • Authorizes the program to negotiate drug prices directly with manufacturers and suppliers
  • Allows the program to partner with other states or the federal government to leverage economies of scale
  • Provides an initial $500 million in funding to establish the manufacturing facilities and operations

Affected Parties and Impacts

  • Individuals and families who struggle to afford necessary prescription medications would benefit from lower drug prices and increased access
  • Private pharmaceutical companies may face increased competition and pressure on profit margins from the state-run program
  • Healthcare providers, including hospitals and pharmacies, could see reduced drug costs, potentially leading to savings that could be passed on to patients
  • State and local governments may experience reduced Medicaid and other healthcare expenditures due to the availability of more affordable drugs

Procedural and Timeline Considerations

SB 1907 has been referred to the Senate Assignments Committee, which will determine if the bill will proceed to a full committee hearing and vote. If the bill is approved by the Assignments Committee, it will then move to the Senate floor for consideration by the full legislative body. If passed by the Senate, the bill would then move to the House for further review and potential amendments before a final vote. If enacted, the Affordable Drug Manufacturing Program would likely require several years to establish the necessary infrastructure and begin production.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.